Neutrophils from the blood of a patient with CGD.
Chronic granulomatous disease (CGD) is a genetic disorder in which white blood cells called phagocytes are unable to kill certain types of bacteria and fungi. People with CGD are highly susceptible to infections, such as Staphylococcus aureus, Serratia marcescens, Burkholderia cepacia, Nocardia species, and Aspergillus species. NIAID aims to improve diagnosis, explore new treatments and preventions, and facilitate genetic counseling for this primary immune deficiency disease.
Current Clinical Research Studies Seeking Volunteers
The following are selected NIAID-supported clinical research activities that are seeking participation by CGD patients. The links lead to full study descriptions, eligibility criteria and contact information.
Use of G-CSF to Obtain Blood Cell Precursors (NCT00001405)
This protocol is designed to study the techniques needed to develop gene therapy or other treatments for certain inherited immune system diseases.
Evaluation of Patients With Immune Function Abnormalities (NCT00128973)
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
Read more about NIAID’s research on Primary Immune Deficiency Diseases (PIDDs).